Table 2:
Event rates and odds ratios for outcomes of interest, by cohort
| Outcome; age, yr | Crude event rate, events/total (rate per 100 patients) |
Event ratio, cohort treated for LTBI v. untreated cohort (95% CI) |
|||
|---|---|---|---|---|---|
| LTBI therapy cohort | Untreated cohort* | Crude OR† | Adjusted OR‡ | Adjusted OR§ | |
| Hospital admission for any reason¶ | |||||
| Total | 1046/9145 (11.4) | 1474/18 290 (8.1) | 1.4 (1.3–1.5) | 1.1 (1.0–1.2) | 1.1 (1.0–1.2) |
| ≤ 35 | 264/4523 (5.8) | 585/9046 (6.5) | 0.9 (0.8–1.0) | 0.8 (0.7–1.0) | 0.8 (0.7–1.0) |
| 36–50 | 255/2533 (10.1) | 370/5066 (7.3) | 1.4 (1.2–1.6) | 1.2 (1.0–1.4) | 1.2 (1.0–1.4) |
| 51–65 | 201/1232 (16.3) | 202/2464 (8.2) | 2.0 (1.6–2.4) | 1.3 (1.0–1.6) | 1.3 (1.1–1.7) |
| > 65 | 326/857 (38.0) | 317/1724 (18.4) | 2.1 (1.8–2.4) | 1.6 (1.3–1.9) | 1.5 (1.3–1.9) |
| Hospital admission for any outcome of interest (hepatic, allergic, GI, hematologic or poisoning)§ | |||||
| Total | 121/9145 (1.3) | 50/18 290 (0.3) | 4.8 (3.5–6.7) | 2.8 (2.0–4.2) | 2.9 (2.0–4.3) |
| ≥ 35 | 17/4523 (0.4) | 9/9046 (0.1) | 3.8 (1.7–8.5) | 4.4 (1.5–12.7) | 4.4 (1.5–12.7) |
| 36–50 | 27/2533 (1.1) | 17/5066 (0.3) | 3.2 (1.7–5.8) | 2.5 (1.2–5.2) | 2.5 (1.2–5.3) |
| 51–65 | 26/1232 (2.1) | 10/2464 (0.4) | 5.2 (2.5–10.8) | 2.6 (1.0–6.3) | 2.2 (0.8–6.4) |
| > 65 | 51/857 (6.0) | 14/1714 (0.8) | 7.3 (4.0–13.2) | 4.0 (2.0–7.9) | 3.8 (1.8–7.8) |
| Hospital admission for hepatic event of interest§ | |||||
| Total | 45/9145 (0.5) | 15/18 290 (0.1) | 6.5 (3.8–11.1) | 3.7 (2.0–6.9) | 2.7 (1.3–5.6) |
| ≤ 35 | 5/4523 (0.1) | 1/9046 (0.0) | 10.0 (1.2–85.6) | NC | NC |
| 36–50 | 8/2533 (0.3) | 7/5066 (0.1) | 2.6 (1.0–6.9) | 2.0 (0.6–6.9) | 1.5 (0.4–5.6) |
| 51–65 | 10/1232 (0.8) | 4/2464 (0.2) | 7.0 (2.3–21.3) | 2.9 (0.7–13.0) | 2.6 (0.4–16.0) |
| > 65 | 22/857 (2.6) | 3/1714 (0.2) | 10.8 (4.2–28.0) | 6.4 (2.2–18.3) | 3.2 (0.9–11.7) |
| Change in regimen** | 226/9145 (2.5) | NA | NA | NA | NA |
| Death from any cause§ | 105/9145 (1.1) | 72/18 290 (0.4) | 2.9 (2.2–3.9) | 1.3 (0.9–2.0) | 1.4 (1.0–2.1) |
| Death within 30 days after any outcome of interest | 7/9145 (0.1) | 3/18 290 (0.0) | 5.3 (1.4–20.1) | 4.8 (0.8–27.7) | 1.4 (0.1–23.6) |
Note: CI = confidence interval; GI = gastrointestinal; LTBI = latent tuberculosis infection; NA = not applicable; NC = no convergence; OR = odds ratio.
An outcome of interest in the untreated cohort refers to an event meeting the same definition as that for LTBI cohort that occurred after the index date for the matched untreated cohort.
ORs were calculated using conditional logistic regression. Cohorts were matched by age and sex.
Logistic model variables were Charlson score, previous hospital admission (one or more hospital admissions in the six months before starting LTBI therapy or matched period for the untreated cohort).
Logistic model variables were previous hospital admission (one or more hospital admissions in the six months before starting LTBI therapy or matched period for the untreated cohort), liver disease, diabetes, renal insufficiency, malignancy, vascular disease and HIV infection or AIDS.
Outcomes were assessed from the first dispensed dose of LTBI therapy to 60 days after the last dispensed prescription (or matched calendar period for controls).
Sequential, nonoverlapping use of isoniazid and rifampin (198/8686 isoniazid to rifampin; 28/459 rifampin to isoniazid).